BACKGROUND: Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000. AIMS: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer. RESULTS: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (d) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a "test and treat" strategy if other causes are excluded. Eradication of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naïve users of non-steroidal anti-inflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility. CONCLUSION: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.
BACKGROUND: Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000. AIMS: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer. RESULTS: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (d) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a "test and treat" strategy if other causes are excluded. Eradication of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naïve users of non-steroidal anti-inflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility. CONCLUSION: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.
Authors: Francis K L Chan; K F To; Justin C Y Wu; M Y Yung; W K Leung; Timothy Kwok; Y Hui; Henry L Y Chan; Cynthia S Y Chan; Elsie Hui; Jean Woo; Joseph J Y Sung Journal: Lancet Date: 2002-01-05 Impact factor: 79.321
Authors: A Zullo; D Vaira; N Vakil; C Hassan; L Gatta; C Ricci; V De Francesco; M Menegatti; A Tampieri; F Perna; V Rinaldi; F Perri; C Papadìa; F Fornari; S Pilati; L S Mete; A Merla; R Potì; G Marinone; A Savioli; S M A Campo; D Faleo; E Ierardi; M Miglioli; S Morini Journal: Aliment Pharmacol Ther Date: 2003-03-01 Impact factor: 8.171
Authors: Brian J McMahon; Thomas W Hennessy; J Michael Bensler; Dana L Bruden; Alan J Parkinson; Julie M Morris; Alisa L Reasonover; Debby A Hurlburt; Michael G Bruce; Frank Sacco; Jay C Butler Journal: Ann Intern Med Date: 2003-09-16 Impact factor: 25.391
Authors: Luigi Gatta; Nimish Vakil; Chiara Ricci; John F Osborn; Andrea Tampieri; Federico Perna; Mario Miglioli; Dino Vaira Journal: Am J Gastroenterol Date: 2004-05 Impact factor: 10.864
Authors: Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo Journal: Aten Primaria Date: 2012-10-01 Impact factor: 1.137
Authors: Guadalupe Ayala; Wendy Itzel Escobedo-Hinojosa; Carlos Felipe de la Cruz-Herrera; Irma Romero Journal: World J Gastroenterol Date: 2014-02-14 Impact factor: 5.742
Authors: Tran T Binh; Seiji Shiota; Lam T Nguyen; Dung D Q Ho; Hai H Hoang; Long Ta; Dung T Trinh; Toshio Fujioka; Yoshio Yamaoka Journal: J Clin Gastroenterol Date: 2013-03 Impact factor: 3.062
Authors: Hashem B El-Serag; John Y Kao; Fasiha Kanwal; Mark Gilger; Frank LoVecchio; Steven F Moss; Sheila E Crowe; Adam Elfant; Thomas Haas; Ronald J Hapke; David Y Graham Journal: Clin Gastroenterol Hepatol Date: 2018-03-17 Impact factor: 11.382